D82.0 Wiskott-Aldrich syndrome

Name of the Condition

• Wiskott-Aldrich syndrome

Summary

Wiskott-Aldrich syndrome is a rare X-linked primary immunodeficiency disorder characterized by a triad of clinical features: eczema, thrombocytopenia (low platelet count), and recurrent infections. The condition results from mutations in the WAS gene, which impairs immune cell function and platelet production, leading to increased susceptibility to infections and bleeding complications.

Causes

Wiskott-Aldrich syndrome is caused by mutations in the WAS gene located on the X chromosome. These genetic mutations disrupt the production or function of the Wiskott-Aldrich syndrome protein (WASP), which is essential for the normal development and activity of immune cells (such as T cells and B cells) and platelets. The disorder is inherited in an X-linked recessive pattern, primarily affecting males.

Risk Factors

• Male sex (due to X-linked inheritance)
• Family history of Wiskott-Aldrich syndrome or related immunodeficiencies
• Presence of WAS gene mutations in maternal relatives

Symptoms

• Recurrent bacterial, viral, or fungal infections (e.g., pneumonia, meningitis, sepsis)
• Eczematous skin rashes, often severe and persistent
• Easy bruising or prolonged bleeding due to thrombocytopenia
• Small-sized platelets (microthrombocytopenia) on blood smear
• Increased risk of autoimmune disorders (e.g., autoimmune hemolytic anemia, vasculitis)
• Higher susceptibility to malignancies, particularly lymphomas

Diagnosis

Diagnosis is based on clinical presentation, laboratory findings, and genetic testing. Key diagnostic steps include: evaluating for thrombocytopenia with small platelets, assessing immune function (e.g., low IgM, impaired antibody responses), and confirming WAS gene mutations. Flow cytometry may show reduced or absent WASP protein in immune cells. Family history and clinical correlation support the diagnosis.

Treatment Options

Treatment focuses on managing symptoms and preventing complications. Options include: prophylactic antibiotics or antivirals to reduce infections, immunoglobulin replacement therapy, platelet transfusions or splenectomy for severe thrombocytopenia, and hematopoietic stem cell transplantation (HSCT) for curative potential. Eczema is managed with topical therapies, and autoimmune complications may require immunosuppressants.

Prognosis and Follow-Up

Prognosis varies depending on disease severity and treatment. Untreated patients often experience recurrent infections and bleeding, with reduced life expectancy. HSCT can improve outcomes, but complications like graft-versus-host disease or infections may occur. Regular follow-up with immunology, hematology, and infectious disease specialists is essential to monitor immune function, platelet counts, and growth/development.

Complications

• Severe or life-threatening infections (e.g., sepsis, meningitis)
• Intracranial or gastrointestinal bleeding due to thrombocytopenia
• Autoimmune disorders (e.g., autoimmune cytopenias, vasculitis)
• Increased risk of lymphomas or other malignancies
• Chronic eczema with secondary skin infections

Lifestyle & Prevention

• Avoid contact with sick individuals to reduce infection risk
• Practice good hygiene and wound care to prevent skin infections
• Use caution with activities that increase bleeding risk (e.g., contact sports)
• Follow vaccination schedules tailored to immunodeficiency (avoid live vaccines)
• Monitor for signs of infection or bleeding and seek prompt care

When to Seek Professional Help

Seek immediate medical attention for: high fever, unexplained bruising or bleeding, severe eczema flares, or signs of infection (e.g., cough, diarrhea, rash). Regular specialist follow-up is critical for monitoring disease progression and treatment efficacy.

Tips for Medical Coders

Code D82.0 is specific to Wiskott-Aldrich syndrome and should be used when the condition is documented. Ensure the diagnosis is clearly supported by clinical findings (e.g., eczema, thrombocytopenia, recurrent infections) and genetic confirmation if available. Do not use this code for other immunodeficiencies or thrombocytopenic disorders without explicit documentation of Wiskott-Aldrich syndrome.